The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurofibromatosis Type 1 Market Research Report 2025
Synopsis
NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas).
The global Neurofibromatosis Type 1 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neurofibromatosis Type 1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurofibromatosis Type 1.
Report Scope
The Neurofibromatosis Type 1 market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurofibromatosis Type 1 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurofibromatosis Type 1 manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Merck
Segment by Type
10 mg
25 mg
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neurofibromatosis Type 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neurofibromatosis Type 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas).
The global Neurofibromatosis Type 1 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neurofibromatosis Type 1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurofibromatosis Type 1.
Report Scope
The Neurofibromatosis Type 1 market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurofibromatosis Type 1 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurofibromatosis Type 1 manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Merck
Segment by Type
10 mg
25 mg
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neurofibromatosis Type 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neurofibromatosis Type 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Neurofibromatosis Type 1 Market Overview
1.1 Product Overview and Scope of Neurofibromatosis Type 1
1.2 Neurofibromatosis Type 1 Segment by Type
1.2.1 Global Neurofibromatosis Type 1 Market Value Comparison by Type (2024-2030)
1.2.2 10 mg
1.2.3 25 mg
1.3 Neurofibromatosis Type 1 Segment by Application
1.3.1 Global Neurofibromatosis Type 1 Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Neurofibromatosis Type 1 Market Size Estimates and Forecasts
1.4.1 Global Neurofibromatosis Type 1 Revenue 2019-2030
1.4.2 Global Neurofibromatosis Type 1 Sales 2019-2030
1.4.3 Global Neurofibromatosis Type 1 Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Neurofibromatosis Type 1 Market Competition by Manufacturers
2.1 Global Neurofibromatosis Type 1 Sales Market Share by Manufacturers (2019-2024)
2.2 Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Neurofibromatosis Type 1 Average Price by Manufacturers (2019-2024)
2.4 Global Neurofibromatosis Type 1 Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neurofibromatosis Type 1, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurofibromatosis Type 1, Product Type & Application
2.7 Neurofibromatosis Type 1 Market Competitive Situation and Trends
2.7.1 Neurofibromatosis Type 1 Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neurofibromatosis Type 1 Players Market Share by Revenue
2.7.3 Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neurofibromatosis Type 1 Retrospective Market Scenario by Region
3.1 Global Neurofibromatosis Type 1 Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Neurofibromatosis Type 1 Global Neurofibromatosis Type 1 Sales by Region: 2019-2030
3.2.1 Global Neurofibromatosis Type 1 Sales by Region: 2019-2024
3.2.2 Global Neurofibromatosis Type 1 Sales by Region: 2025-2030
3.3 Global Neurofibromatosis Type 1 Global Neurofibromatosis Type 1 Revenue by Region: 2019-2030
3.3.1 Global Neurofibromatosis Type 1 Revenue by Region: 2019-2024
3.3.2 Global Neurofibromatosis Type 1 Revenue by Region: 2025-2030
3.4 North America Neurofibromatosis Type 1 Market Facts & Figures by Country
3.4.1 North America Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.4.3 North America Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neurofibromatosis Type 1 Market Facts & Figures by Country
3.5.1 Europe Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.5.3 Europe Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurofibromatosis Type 1 Market Facts & Figures by Country
3.6.1 Asia Pacific Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.6.3 Asia Pacific Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neurofibromatosis Type 1 Market Facts & Figures by Country
3.7.1 Latin America Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.7.3 Latin America Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurofibromatosis Type 1 Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.8.3 Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurofibromatosis Type 1 Sales by Type (2019-2030)
4.1.1 Global Neurofibromatosis Type 1 Sales by Type (2019-2024)
4.1.2 Global Neurofibromatosis Type 1 Sales by Type (2025-2030)
4.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
4.2 Global Neurofibromatosis Type 1 Revenue by Type (2019-2030)
4.2.1 Global Neurofibromatosis Type 1 Revenue by Type (2019-2024)
4.2.2 Global Neurofibromatosis Type 1 Revenue by Type (2025-2030)
4.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
4.3 Global Neurofibromatosis Type 1 Price by Type (2019-2030)
5 Segment by Application
5.1 Global Neurofibromatosis Type 1 Sales by Application (2019-2030)
5.1.1 Global Neurofibromatosis Type 1 Sales by Application (2019-2024)
5.1.2 Global Neurofibromatosis Type 1 Sales by Application (2025-2030)
5.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
5.2 Global Neurofibromatosis Type 1 Revenue by Application (2019-2030)
5.2.1 Global Neurofibromatosis Type 1 Revenue by Application (2019-2024)
5.2.2 Global Neurofibromatosis Type 1 Revenue by Application (2025-2030)
5.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
5.3 Global Neurofibromatosis Type 1 Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Neurofibromatosis Type 1 Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Neurofibromatosis Type 1 Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Neurofibromatosis Type 1 Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Neurofibromatosis Type 1 Product Portfolio
6.2.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurofibromatosis Type 1 Industry Chain Analysis
7.2 Neurofibromatosis Type 1 Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurofibromatosis Type 1 Production Mode & Process
7.4 Neurofibromatosis Type 1 Sales and Marketing
7.4.1 Neurofibromatosis Type 1 Sales Channels
7.4.2 Neurofibromatosis Type 1 Distributors
7.5 Neurofibromatosis Type 1 Customers
8 Neurofibromatosis Type 1 Market Dynamics
8.1 Neurofibromatosis Type 1 Industry Trends
8.2 Neurofibromatosis Type 1 Market Drivers
8.3 Neurofibromatosis Type 1 Market Challenges
8.4 Neurofibromatosis Type 1 Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
